myNEO Therapeutics

TLDR

myNEO Therapeutics develops an ImmunoEngine platform for personalized cancer vaccine neoantigen discovery, epitope prediction, and mRNA codon optimization.

Overview

myNEO Therapeutics' ImmunoEngine platform combines immunology expertise with AI-driven technologies for personalized neoantigen discovery in cancer vaccines and T-cell therapies, mRNA codon optimization, ADA risk prediction, and multi-epitope construct design. The company serves vaccine developers, biologics innovators, and pharma partners, and offers a proprietary asset library of immunotherapy targets for partnering and licensing.